Autoimmune hemolytic anemia. II. Therapeutic aspects.
D000614:Aminocaproates / Q000627:therapeutic use; D000744:Anemia, Hemolytic, Autoimmune / Q000628:therapy*; D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001787:Blood Group Incompatibility; D001803:Blood Transfusion; D005078:Exchange Transfusion, Whole Blood / Q000009:adverse effects; D005938:Glucocorticoids / Q000627:therapeutic use; D006400:Hematocrit; D006493:Heparin / Q000627:therapeutic use; D007106:Immune Sera; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D011830:Radiation Effects; D012911:Snakes; D013154:Spleen / Q000528:radiation effects; D013156:Splenectomy; D013934:Thymectomy; D014688:Venoms
D000614:Aminocaproates; D000961:Antilymphocyte Serum; D005938:Glucocorticoids; D007106:Immune Sera; D007166:Immunosuppressive Agents; D014688:Venoms; D006493:Heparin